Novel p53-MDM2 Inhibitor Plus Ribociclib Demonstrates Anticancer Activity in Liposarcoma Subset
Siremadlin plus ribociclib showed manageable safety and encouraging efficacy in MDM2/CDK4-amplified liposarcoma patients, with a median overall survival of 23 months, highlighting the potential of targeting both MDM2 and CDK4/6 pathways.
© Copyright 2024. All Rights Reserved by MedPath